Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing - PubMed (original) (raw)
Review
. 2014:42 Suppl 4:S375-82.
doi: 10.3233/JAD-141470.
Affiliations
- PMID: 25190629
- DOI: 10.3233/JAD-141470
Review
Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing
Sylvie Belleville et al. J Alzheimers Dis. 2014.
Abstract
In this paper, we review studies that have investigated whether neuropsychological, neuropsychiatric, and neuroimaging measures predict decline to Alzheimer's disease (AD). Prospective neuropsychological studies indicate that cognitive performance may be an excellent indicator of future progression from mild cognitive impairment (MCI) to AD, particularly when episodic memory is combined with tasks relying on executive control and language tasks. Research on neuropsychiatric symptoms reveal that depression, apathy, anxiety, and sleep disturbances can contribute to predictive models, though their sensitivity is typically lower than that found with cognitive measures. Finally, different structural brain imaging markers reveal excellent predictive accuracy. The paper discusses issues that will have to be addressed in future studies. First, it will be necessary to increase the evaluation of combined markers, as this may considerably improve predictive accuracy. Second, it will be necessary to move to earlier stages than MCI in order to expand the detection window. Third, processes of compensation and plasticity will have to be better investigated as research moves into earlier stages. The Consortium for the early identification of AD-Quebec (CIMA-Q) is presented as an instance of this approach, and potential batteries of measures are proposed.
Keywords: Alzheimer's disease; cognition; early detection of disease; longitudinal studies; mild cognitive impairment; neuroimaging; neuropsychiatry.
Similar articles
- Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects.
Richard E, Schmand B, Eikelenboom P, Yang SC, Ligthart SA, Moll van Charante EP, van Gool WA; Alzheimer’s Disease Neuroimaging Initiative. Richard E, et al. Dement Geriatr Cogn Disord. 2012;33(2-3):204-9. doi: 10.1159/000338239. Epub 2012 May 11. Dement Geriatr Cogn Disord. 2012. PMID: 22722671 - Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy.
Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Spalletta G. Palmer K, et al. J Alzheimers Dis. 2010;20(1):175-83. doi: 10.3233/JAD-2010-1352. J Alzheimers Dis. 2010. PMID: 20164594 - MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H. de Leon MJ, et al. J Intern Med. 2004 Sep;256(3):205-23. doi: 10.1111/j.1365-2796.2004.01381.x. J Intern Med. 2004. PMID: 15324364 - Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
Ruan Q, D'Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z. Ruan Q, et al. BMC Geriatr. 2016 May 16;16:104. doi: 10.1186/s12877-016-0281-7. BMC Geriatr. 2016. PMID: 27184250 Free PMC article. Review. - Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
Levey A, Lah J, Goldstein F, Steenland K, Bliwise D. Levey A, et al. Clin Ther. 2006 Jul;28(7):991-1001. doi: 10.1016/j.clinthera.2006.07.006. Clin Ther. 2006. PMID: 16990077 Review.
Cited by
- Cognitive Stimulation with Music in Older Adults with Cognitive Impairment: A Scoping Review.
Raglio A, Figini C, Bencivenni A, Grossi F, Boschetti F, Manera MR. Raglio A, et al. Brain Sci. 2024 Aug 22;14(8):842. doi: 10.3390/brainsci14080842. Brain Sci. 2024. PMID: 39199533 Free PMC article. Review. - Exploring cognitive progression subtypes in the Framingham Heart Study.
Ding H, Wang B, Hamel AP, Karjadi C, Ang TFA, Au R, Lin H. Ding H, et al. Alzheimers Dement (Amst). 2024 Mar 21;16(1):e12574. doi: 10.1002/dad2.12574. eCollection 2024 Jan-Mar. Alzheimers Dement (Amst). 2024. PMID: 38515438 Free PMC article. - Anxiety and Alzheimer's disease pathogenesis: focus on 5-HT and CRF systems in 3xTg-AD and TgF344-AD animal models.
Reyna NC, Clark BJ, Hamilton DA, Pentkowski NS. Reyna NC, et al. Front Aging Neurosci. 2023 Nov 10;15:1251075. doi: 10.3389/fnagi.2023.1251075. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38076543 Free PMC article. Review. - Predictive factors for Alzheimer's disease progression: a comprehensive retrospective analysis of 3,553 cases with 211 months follow-up.
Özge A, Ghouri R, Öksüz N, Taşdelen B. Özge A, et al. Front Neurol. 2023 Aug 24;14:1239995. doi: 10.3389/fneur.2023.1239995. eCollection 2023. Front Neurol. 2023. PMID: 37693748 Free PMC article. - Hippocampal Volume and Episodic Associative Memory Identify Memory Risk in Subjective Cognitive Decline Individuals in the CIMA-Q Cohort, Regardless of Cognitive Reserve Level and APOE4 Status.
Caillaud M, Maltezos S, Hudon C, Mellah S; Consortium for the Early Identification of Alzheimer’s Disease-Quebec; Belleville S. Caillaud M, et al. J Alzheimers Dis. 2023;94(3):1047-1056. doi: 10.3233/JAD-230131. J Alzheimers Dis. 2023. PMID: 37355896 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical